Systemic cytokines related to memory function 6-9 months and 12-15 months after SARS-CoV-2 infection.

Systemic cytokines related to memory function 6-9 months and 12-15 months after SARS-CoV-2 infection.

Publication date: Sep 30, 2024

Cognitive symptoms persisting beyond the acute phase of COVID-19 infection are commonly described for up to 2 years after infection. The relationship between cognitive performance, in particular episodic memory processes observed chronically after infection, and cytokine levels in the acute phase of COVID-19 has not yet been identified in humans. To determine whether the levels of cytokines IL1β, IL-6 and TNFα secreted in the acute phase of SARS-CoV-2 infection are associated and predict verbal and visuospatial episodic memory performance in humans 6 to 9 months and 12 to 15 months post-infection. The associations and predictive value of the concentration of cytokines measured in acute phase (IL-1β, IL-6, TNFα) from plasma samples of N = 33 hospitalized COVID-19 patients (mean age 61 years, 39-78, 65% in intensive care) in relation to their verbal and visuospatial episodic memory performance measured at 6-9 months and 12-15 months post-infection were analyzed. To do this, we used Spearman correlations and generalised linear mixed models. IL-1β levels were associated with verbal episodic memory total recall scores 6-9 months post-infection. At 12-15 months post-infection IL-6 predicted verbal episodic memory score. This study demonstrated that the severity of inflammatory reaction at acute phase of SARS-CoV-2 infection predicts verbal episodic memory performance in the long-term post-infection.

Open Access PDF

Concepts Keywords
15months Adult
2years Aged
Covid Cognition
Cytokines COVID-19
Spearman COVID-19
Cytokines
Cytokines
Female
Humans
Immunity
Interleukin-1beta
Interleukin-1beta
Interleukin-6
Interleukin-6
Long COVID
Male
Memory
Memory, Episodic
Middle Aged
Post-COVID
SARS-CoV-2
SARS-CoV-2
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH infection
drug DRUGBANK Coenzyme M
disease MESH Long COVID
drug DRUGBANK Diethylstilbestrol
disease MESH sequelae
disease MESH memory loss
disease IDO symptom
disease MESH anosognosia
disease MESH viral infection
disease MESH pneumonia
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
disease MESH cognitive decline
disease MESH syndrome
drug DRUGBANK Ademetionine
disease MESH Education level
disease MESH Encephalopathy
disease IDO history
disease MESH neurological disorders
disease MESH psychiatric disorders
disease IDO immunosuppression
disease IDO process
pathway REACTOME Influenza Infection
pathway REACTOME Immune System
disease MESH neuroinflammation
drug DRUGBANK Indoleacetic acid
disease IDO cell
disease IDO blood
disease MESH cancer
disease MESH substance use
drug DRUGBANK Trestolone
disease MESH inflammation
disease MESH autoimmunity
pathway REACTOME Glucose metabolism
pathway KEGG Influenza A
disease MESH bacterial pneumonia
disease MESH depression
disease MESH Alzheimer’s disease
disease MESH Parkinson’s disease
disease MESH HIV 1 associated cognitive motor complex
drug DRUGBANK Nonoxynol-9
disease IDO production
disease MESH dementia
pathway REACTOME Reproduction

Original Article

(Visited 3 times, 1 visits today)